OECD Reads Portugal's Chronic-Disease Bill at 4.12% of GDP a Year Through 2050 — Diabetes Alone Costs 1.37%, Cancer 1.23%, Cardiovascular 0.81%, Respiratory 0.71% in the New Article-IV-Style Health Audit

The OECD's new flagship report on non-communicable diseases — Os Benefícios para a Saúde e a Economia do Combate às Doenças não Transmissíveis — lands this week with a hard number for Portugal: roughly 4.12% of GDP every year between 2026 and 2050 will be eaten by the four major chronic-disease groups, against a counterfactual where the disease burden is removed. That is the OECD's central scenario. The headline 4% number applies across the bloc, but Portugal sits at the upper end of the European tape, behind only a handful of southern and eastern European economies on the same metric.

The four diseases, by share of GDP

The OECD breaks the Portuguese print into its components. Diabetes carries the largest share at 1.37% of GDP, followed by cancer at 1.23%, cardiovascular diseases at 0.81% and respiratory diseases at 0.71%. Diabetes leads everywhere in the OECD database because the through-life productivity and treatment cost runs higher than any other single condition once prevalence climbs above 8% of the adult population — Portugal's adult-diabetes prevalence is around 9.8% on the most recent INE-Direção-Geral da Saúde tape. The cancer line is dominated by mortality-driven labour-supply loss; the cardiovascular and respiratory lines split roughly two-thirds treatment cost and one-third labour-supply effect.

The prevalence chart that anchors the number

The OECD anchors its 24-year projection in the prevalence growth recorded between 1990 and 2023 across the bloc. Over that 33-year window, diabetes prevalence rose 87% — the steepest of the four — followed by respiratory diseases at +49%, cancer at +36% and cardiovascular at +27%. Portugal's lines moved broadly with the OECD median on cardiovascular and cancer, but ran slightly hotter than the bloc on diabetes given the ageing demographic profile and the share of the workforce in metabolically taxing low-wage occupations. The compounded effect over 24 years is what produces the 4% figure.

The counterfactual: 3.8% extra GDP, 41% lower health spend

The OECD's most quoted line is what would happen if the bloc eliminated the four chronic-disease groups entirely. The model returns a 3.8% lift to average annual GDP across the 24-year window, and a 41% cut to total health spending — the second number captures both treatment cost and the indirect drag from family caregivers leaving the labour market. The framework is the same one the OECD has used for its tobacco, obesity and alcohol audits since the late 2010s, run at the country level with national health-system inputs.

What Lisbon does with the number

The OECD's policy recommendations are familiar: an integrated approach combining public-health policy that promotes healthy behaviours, supportive environments — the urban-planning and food-labelling kind — and a strengthened primary-care line as the front door for both prevention and chronic-condition management. The strengthened-primary-care recommendation lands awkwardly into a Portuguese tape that is still short roughly 1.7 million users without an assigned family doctor as of the latest ACSS print, and into a SNS doctor package that left Conselho de Ministros only on 7 May. The OECD report effectively sets the budget case for the next round of SNS-reform horse-trading at 4% of GDP — recurring, every year — versus the marginal cost of a denser primary-care network. That is the comparison Finance Minister Joaquim Miranda Sarmento will be made to run by the OECD's country team when the next Article IV-equivalent peer review arrives.

Sources: OECD report Os Benefícios para a Saúde e a Economia do Combate às Doenças não Transmissíveis; PÚBLICO, 10 May 2026; INE-DGS prevalence data; ACSS primary-care registers.